Good morning, ladies and gentlemen. And welcome to the BioCryst’s Fourth Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will host a question-and-answer session and our instructions will be given at that time. [Operator Instructions].

And as a reminder, this conference call is being recorded for replay purposes. It is now my pleasure to hand the conference over to John Bluth. Sir, you may begin..

Thanks, Brian. Good morning, and welcome to BioCryst's fourth quarter and full year 2018 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating on the call with me today are CEO, Jon Stonehouse; CFO, Tom Staab; Chief Medical Officer, Dr.

Bill Sheridan; and Chief Commercial Officer, Lynne Powell. Following their remarks, we will answer your questions. Before we begin, I want to direct your attention to Slide 2, which discusses our use of forward-looking statements and potential risk factors regarding an investment in BioCryst.

As detailed on the slide, today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements.

These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements.

For additional information including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. I'd now like to turn the call over to Jon Stonehouse..

HAE, complement-mediated diseases and FOP, where we plan to begin a Phase 1 trial with BCX9250 in the second half of the year. We're building a company that will soon have a highly differentiated marketed product and a growing clinical pipeline, all focused on bringing patients with rare diseases and oral therapy, and a shot at having a normal life.

We have also recently extended our cash runway further into 2020 with the addition of the $100 million debt facility we announced last month. This provides the company with additional financial flexibility to support these exciting programs. Now, I'd like to hand the call over to Bill for an update on the HAE program and more details about 9930.

Bill?.

Thank you, Jon. I'll start with the HAE program and the data we just reported last week from the ZENITH-1 trial at the AAAAI Meeting.

You’ll recall that ZENITH-1was a Phase 2 dose ranging proof-of-concept trial designed to estimate treatment effect, evaluate safety and tolerability, select clinically meaningful endpoints for a Phase 3 registration trial, and to identify the distance to advance. We are thrilled that ZENITH-1 clearly achieved all its objectives.

This trial also broke new ground as the first prospective randomized placebo-controlled trial of acute HAE treatment administered at-home by the patients early in the course of the attack, with a goal of stopping escalation and attack symptoms.

This aligns with modern treatment guidelines and is an important element of treatment that has got a disease impact. We selected the three dose levels to test based on clinical PK profiles.

As you can see on Slide 9, we had previously reported at all HAE subjects in a PK study dose considering 150 milligrams had drug levels more than 8 times EC50 within 30 minutes sustained through 24 hours post dose.

This long duration of action is important given the recent evidence of the high rate of re-dosing with short half life acute HAE treatments.

With ZENITH-1 completed, we now have real world controlled clinical trial results confirming its rapid onset of action and 24 duration of effect, with single oral doses of 7353 and to create dose response going from 250 milligrams to 750 milligrams.

As Jon noted, in September, we reported results showing clinically meaningful and statistically significant treatment effects from our 750 milligram dose, together with a favorable safety and tolerability profile, strongly supporting advancing the 750 milligram dose to Phase 3.

Most noteworthy additional data from the 250 milligram and 500 milligram cohorts reported last week at AAAAI was the clear dose response we observed across multiple endpoints. This is reflected on Slide 12 with the examples of improvements in visual analog scale scores and proportion of subjects who use rescue medicine.

As detailed on the safety summary Slide 13, 7353 was generally safe and well tolerated with no notable differentiation from the adverse event profile from placebo. The next step for the acute program for 7353 is to meet with regulators to discuss the Phase 3 trial with goal of starting patient enrollment over the summer.

The prophylactic program also continues to make excellent progress. As Jon noted, the 24-week safety and efficacy readout from APeX-2 is on schedule for the second quarter. As a reminder, the trial enrolled very quickly. In fact, over-enrolled, with 121 subjects and is now powered at 99% to detect a 50% reduction in attack rate versus placebo.

We look forward to sharing the results with you in the second quarter. Both APeX-2 and our safety trial APeX-S continue to progress well. Patients have now started to enter an extension period beyond 48 weeks of dosing. That is continued daily oral treatment through 96 weeks.

In parallel, the team has made an excellent start on our regulatory filings and we remain on schedule to file a New Drug Application with the FDA by the end of the year and a Marketing Authorization Application with the EMA in the first half of 2020.

We recently enrolled our first patient in the APeX-J trial in Japan, which is being conducted to support the J-NDA. This trial is a 24-subject, randomized, placebo-controlled trial, similarly designed to APeX-2, using the same dosage of 7353.

Because there are no prophylactic treatments for HEA approved in Japan, the unmet need there for HAE patients is high and clear. Now, I'm very excited to tell you more about 9930, our oral Factor D inhibitor for complement-mediated diseases, which is advancing into Phase 1 clinical development.

Today, patients with complement-mediated diseases either have no specific treatment options or must be treated with lifelong IV infusions. The only approved therapies in this field work to inhibit a terminal component of the complement cascade C5.

Factor D is critical enzyme in the alternative complement pathway that drives amplification of the entire complement system upstream to C5. With this mechanism of action of the Factor D inhibitor, we believe that 9930 is a potential treatment for a broader range of complement-mediated disorders.

Potential indications for 9930 include many rare diseases of the kidney, blood, and nervous system. Treatment with oral 9930 could fundamentally transform patients' lives and improve on existing therapies.

The preclinical profile of oral 9930 is extremely attractive, and after oral dosing in non-human primates, complement activity was immediately and dramatically suppressed. In preclinical studies, this compound was potent, specific and had a very wide safety margin. Let me now walk you through the data that has us so excited.

On slide 18, the left hand table reports the consistent in-vitro potency of 9930 across multiple complement assays. These include measurement of Factor D enzymatic action, complement-mediated destruction of red blood cells of hemolysis and deposition of complement enzyme C3 fragment on the surface of red cells for patients with PNH.

The specificity values in the right-hand table indicate a low likelihood of off-target effects on other serine proteases. An important preclinical proof-of-concept test for 9930 was to dose animals orally and measure its effects on the complement cascade.

This experiment answers the fundamental question, does enough drug get absorbed to work on the target. We use standard assay in this field hemolysis of heterozygous red cells.

On Slide 19, you can see that after dosing non-human primates, 9930 rapidly suppressed complement activity with near complete suppression of complement-mediated hemolysis by 24 hours despite the 50% lower potency of 9930 on non-human primate Factor D compared to human Factor D.

Of note, the drug exposure needed was a fraction of the no observed adverse event level, or NOAEL exposure, in preclinical safety studies. The preclinical safety margin of 9930 that supports entry into clinical trials is also very encouraging.

On slide 20, you can see first, that with still very high drug exposures proportional to dose and second that drug levels for the NOAELs of 9930 were more than 500 times greater than the estimated therapeutic target level with an associated human equivalent dose of more than 5,000 milligrams.

This dose is so much higher than needed for target pharmacodynamic effects that it will never be necessary to study it in the clinic. The preclinical safety and pharmacology profile of 9930 should provide us with tremendous dosing flexibility.

Based on its preclinical PK PD and safety profile, we expect that we'll be able to safely dose oral 9930 in people and achieve drug levels that block the complement cascade. The proof-of-concept can be very efficient in this field. Complement assays and many validated and highly predictive disease related biomarkers are already very well established.

By using these tools in our clinical studies, we will be able to see proof-of-concept in a matter of days or weeks in most cases, with very small patient numbers. We look forward to seeing the results from our single ascending dose and multiple ascending dose Phase 1 trial when it reads out in the fourth quarter.

In summary, the body of preclinical evidence for 9930 suggests that we have a great molecule here. We are driving hard to-proof-of concept in patients and we can do this very quickly because complement assays and disease biomarkers are so good, needing very few patients to generate convincing evidence.

We believe oral 9930 could represent a pipeline and a product with the potential to address many different complement-mediated disorders. Now, I'd like to turn the call over to Lynne..

Thank you, Bill. I'm also very excited about the potential of 9930 from a commercial perspective. As you can see on Slide 22, the single approved IV infusion therapy for complement-mediated disorders has already generated $3.6 billion in annual sales, with just three approved indications.

Interestingly, the majority of these sales come from outside the US, primarily from Europe. We believe the future market for complement inhibitors could exceed $10 billion based on the range of potential indications.

An oral Factor D inhibitor, like 9930, has the potential to capture a significant share of that opportunity because of its upstream inhibitory activity, and of course, the significant advantage of oral administration compared to lifelong infusions.

With full global rights to 9930 and the relatively quick proof-of-concept, we look forward to seeing the data later this year. In the near term, we’re anticipating the readout of our 24-week safety and efficacy data from APeX-2 next quarter.

Our key focus is preparing the organization for launch of what will be the first once-daily oral medicine to prevent HAE attacks. As you track the HAE market and recent competitive launches, you can see on slide 23 the market mix continues to shift from acute-only to prophylactic therapy as better prophylactic agents become available to patients.

Based on our recent conversations with physicians at AAAAI and our own market research, we expect the availability of 7353 will further accelerate the movement of the market from acute to prophylactic.

Over the past several years, we have conducted market research with HAE patients and their physicians, both prior and post the new therapies entering the market and the results have been remarkably consistent. On slides 24 and 25, you can see some of our most recent round of research completed in late 2018.

What is striking is that even with the new prophylactic treatment options that are available, patients continue to state their strong preference for an oral option, with 89% of patients, including 10 out of 14 TAKHZYRO patients saying that if an oral option were available, they would try it.

The allergists who treat HAE say the same, with 97% expecting that patients would try an oral option. Our focus will be to deliver on this desire with a product that patients can access and to provide best-in-class customer service. Now, I'd like to turn the call over to Tom..

Thank you, Lynne. As Jon mentioned, we took an important step in the first quarter to further extend our cash runway and enhance our financial flexibility by closing a $100 million secured credit facility.

This $100 million facility represented a modification and an enhancement of our existing $30 million secured credit facility outstanding at December 31st.

This new agreement provided $20 million of immediate additional non-dilutive capital to extend our cash runway, and provides flexibility for us to draw another $50 million of milestone based non-dilutive capital at our option.

In addition to the non-dilutive cash added to the balance sheet in the first quarter, $30 million is available to us at our option following positive APeX-2 data, which is considered sufficient to file a new drug application. We ended 2018 with $128 million in cash and investments.

Of course, this amount does not include the $20 million we added upon the first quarter modification of our credit facility.

With our existing cash-on-hand, the $20 million of proceeds we received in the February closing, as well as the contingent proceeds from the modified credit facility, we have a strong cash position that provides us the resources to fund our development programs and commercial preparations deeper into 2020, and well past the readout of APeX-2 and the filing of our NDA application for a prophylaxis HAE indication.

Our detailed fourth quarter and year-end financial results can be found in the press release we issued this morning, but I'd like to take some time to highlight some information for you given the many milestones we anticipate across our programs in 2019. As you see on Slide 27, revenue for the fourth quarter of 2018 decreased to $2.7 million.

As compared to fiscal 2018 levels, we expect slightly more development activity and related revenue from Galidesivir in 2019 due to planned clinical activity.

In addition, we expect to ship and record just under $7 million of RAPIVAB product sales to the US Government under our procurement contract, with the expectation that this shipment will occur before the end of September. Fourth quarter 2018 R&D expenses increased to $23.4 million from $16.9 million in the fourth quarter of 2017.

Specifically, the increase was due to the ongoing APeX-2, APeX-S, APeX-J trials and the completed ZENITH-1 trial, as well as wrapping up preclinical activities that allow us to conduct Phase 1 trials in both our complement and FOP programs in 2019.

Given the significant clinical development activities in our for rare disease programs and continued development activity with Galidesivir and peramivir, we expect our 2019 R&D expenses will increase from 2018 levels. This increase is reflected in our 2019 guidance that I will discuss in a few moments.

General and administrative expenses were $4.5 million and decreased slightly in the fourth quarter of 2018. However, upon receiving positive APeX-2 data in the second quarter of this year, we anticipate our G&A expenses will increase as we build out the necessary commercial and medical affairs infrastructure to successfully launch 7353 in 2020.

Regarding operating guidance, we expect our 2019 cash utilization to be in the range of $105 million to $130 million, and our 2019 operating expenses to be in the range of $120 million to $145 million.

This operating expense, as in past years, excludes equity-based compensation due to difficulty in reliably projecting this expense as it is impacted by the volatility and price of our stock, as well as by the vesting of outstanding performance-based stock options.

Furthermore, with the modification of our secured credit facility, and looking below the operating line, you should expect higher interest expense for 2019 because of higher debt balances than those in 2018.

2019 is off to an outstanding start, with strong clinical data from the full ZENITH-1 dataset, advancement of our very exciting compound 9930 into the clinic, and added financial flexibility for the company with our credit facility modification. We look forward to sharing the APeX-2 results with you when the trial reads out next quarter.

This concludes our prepared remarks and we would now like to take it to your questions or answer your questions.

Brian?.

Thank you, sir. [Operator Instructions]. And our first question will come from the line of Jessica Fye with JPMorgan. Your line is now open..

Thanks for taking our questions. This is Daniel for Jessica. Can you talk about the technique for confirming attacks in APeX-2, and how this compares to APeX-1? And I have a quick follow-up. Thanks..

Sure. Hi, Daniel. It's Bill. The attacks in APeX-2 are confirmed by the site investigator in a telephone call within approximately two business days of when they are notified a subject has had an attack electronically. The subjects in the study carry an electronic diary, each day they record that whether or not they've had an attack.

And that gives the site investigator the opportunity to go through a series of standardized questions about symptoms, treatment, follow up and the like, and make a judgment that's recorded then as investigator assessed attacks and that becomes the primary analysis dataset for efficacy for the study.

In contrast, in APeX-1, we had a remote expert panel of three expert physicians, who received a spreadsheet with what was recorded in a diary from the patient, but they had no ability -- no facility to contact the patient or ask them questions. So that's a significant difference..

Got it. Thank you. And then, for the ZENITH-1, for acute attacks, a number of endpoints were assessed.

Can you maybe talk about what potential endpoint for Phase 3 we are thinking that would best highlight the product profile?.

Well, we are very pleased that what we saw was a rapid onset of action and sustained duration, that's what patients need for an acute treatment and we've got a number of endpoints to choose from. It's a highly competitive area, so at this stage, no, we're not going to disclose what we are advancing as primary endpoints for Phase 3.

And as I mentioned on the call, the next step is to meet with regulators to discuss the design and then finalize the design and start the study in the summer. So we're looking forward to that..

Thank you. And our next question will come from the line of Maury Raycroft with Jefferies. Your line is now open..

First question is for 9930.

I'm wondering if you can comment on what the half-life is, and if you're not disclosing the half-life, is there a strategy here to have a molecule with longer or shorter half-life? And then, how does that play into the clinical indications that you're going to pursue?.

Sure. Hi, Maury. We haven't disclosed the half-life. We will find out what it is in humans which is what really matters and we'll find that out pretty quickly.

We actively -- in all of our drug development programs, including 9930, we actively work on all of the traditional tactics for formulation development, but the first step here is to find out what its exposure profile is and its PD profile and safety profile is in people. So that will be exciting..

Do you have an idea based on the non-human primate data?.

No. We've got non-clinical experience in several non-clinical species. The predictability of human half-life on the basis of non-clinical findings is rather weak. It's so wide that people in the literature declare success if they get it within three fall, by the way, so that's not particularly helpful. So I think we really need the human data..

Okay.

And can you talk about which indications that you're considering?.

All of them. Sorry. I think that what's fascinating here is that over the last, I'd say, 20 to 30 years, the explosion of understanding of how abnormal activation of the complement system or suppression of its inhibitors leads to disease outcomes that are really very, very significant across a broad range of diseases.

And we're seeing from the initial indications of IV treatments just what a striking difference adequate treatment can make. So we will pick things that are the most feasible, where the medical need is high and it's very attractive..

Yes. This concept of pipeline in a molecule is really important for people to understand. You could build a whole company around an oral Factor D inhibitor because there's so much opportunity. So we're extremely excited with this program..

Great.

And I'll ask one more question, just based on the half-life with 7353 for acute HAE, I guess, how confident are we that you can -- or how confident are you that you can talk about some of the supporting evidence that re-dosing, particularly with Firazyr in mind, is because of short half-life, or is it because of patients waiting too long to dose?.

Yes. The half-life -- Bill, correct me if I'm wrong, is in the 50 to 70 hour range. So -- and you saw from the clinical data that the Kaplan-Meier curve on reaching for rescue medicine got wider and wider, as you went across the 24-hour period. So, the likelihood that there's a re-dosing necessary appears to us to be low with 7353.

And what's really interesting is, now there are two sets of data showing real-world experience with the short half-life acute therapies. The first one was done by the group in Berlin. I think, late last year that was published, showed a 40% re-dose rate with Firazyr in the real world.

And then, at that AAAAI Meeting, the HAE Association had a poster and I think it was around 30%, was the re-dose rate.

And so that's a problem, it's a problem from a payer perspective, that you've got to pay for an additional dose and it's a problem from a patient perspective, because the last thing you want to do is, be questioning whether or not you're going to get full coverage with the dose you took.

So for emotional reasons, financial reasons having a long-acting acute therapy is a must..

Thank you. And our next question will come from the line of Brian Abrahams, RBC Capital Markets. Your line is now open..

Hey, guys. This is Owen on for Brian. Thanks for taking the questions and congrats on the recent progress.

Just on the market research slide you presented in prophylactic, the question about switching from an injectable to an oral, did that include any explicit assumptions on efficacy? And along those lines where are you viewing the bar for APeX-2, given the differentiation as an oral and can you share any real -- any learnings on the real-world use you have seen from following the continued TAKHZYRO launch? Thank you..

Yes. So, in terms of the market research data, we had seen that our product was preferred compared to the other products. And if you look at slide 24, this situation had the question asked within a period of showing profiles of drugs. So a profile of the Phase 2, profile of 7353 and the marketed profiles of TAKHZYRO and HAEGARDA.

And as you can see a very, very good interest in moving to an oral product. And if we look similarly at the physicians slide, they really do show an interest in really recommending and allowing patients to move to an oral therapy..

I think, Alan, one other really important piece that we see in both, when we did this research a while back before the new therapies were on the market, and now with the new therapies on the market, is a consistency that patients want to try an oral. And so, I think our trial usage is going to be really high.

We see that consistent with all the market research we've done. And so then it's a matter of what experience do they have on the drug and will they stay on it.

And we think that, if you do the simple math of looking at injections with something like TAKHZYRO, where you have an injection every two weeks, that's many injections over the course of the year versus if you have a breakthrough attack on your oral therapy and you got to inject Firazyr for example, it's way less.

So we think that the trial usage is going to be very high and we think many patients are going to stay on therapy, because they don't want an injection..

Thank you. And our next question will come from the line of Tyler Van Buren with Piper Jaffray. Your line is now open..

I guess first question was on 9930 as well.

Can you speak a little bit more about the competitive landscape with respect to Factor D inhibitors and specifically, what makes you guys so excited? Historically, has the difficulty been developing a molecule that's selective enough or it doesn't hit the other serine protease, or is the potency or all of the above, some additional thoughts would be helpful?.

Yes. So, it's, I would say, complement-mediated diseases is crowded, but the vast majority -- dozens are injectable, and there's only one other oral competitor and in a market that's as big, we think that's a really nice opportunity for 9930.

The second half of your question was around specificity, this is a tough target, that's why there aren't a lot of oral Factor D inhibitors, like other targets we've gone after, our ability and the capability that we have with the group in Birmingham is to identify potent inhibitors, but also specific to that target and so we can go after things like serine proteases and kinases and the like, because we have both potency and specificity..

Yes. And I think that we are thrilled with the data. We've got excellent potency specificity PK PD safety profile in the nonclinical body of evidence. So, we are very much looking forward to getting a clinical data..

Based on everything you're seeing clinically, does it compare fairly well to the injectables or how does it compare? And also how do you think the mechanism compares to a C3 inhibitor?.

So in conversations we've had with expert advisors, who we've been having conversations with about the program, since we mentioned oral Factor D inhibitor, we get responses like, wow, that's the Holy Grail of complement therapeutics. And the reason for that reaction -- and I'm not kidding, that was a direct quote.

The reason for that reaction is because the alternative pathway amplifies all of the different mechanisms of initiation of the complement cascade and Factor D is absolutely essential to do that. So if you block Factor D and block amplification, no matter how complement got stimulated in the first place, that opens up every disease.

So, for example, there are great reviews on -- for kidney diseases that are driven by abnormalities of inhibitors as the alternative pathway and they're characterized by deposition of the relevant fragments of complement from that pathway that have nothing to do pretty much with the terminal cascade which depends on C5.

And C5 inhibitors can't address the fundamental pathology of the disease, whereas a Factor D inhibitor could. So I think there are two things here. One is you can address all of the current diseases because of the amplification loop, inhibitory aspects and you can address diseases that are too proximal for distal inhibitors to do anything full.

So that -- both of those aspects are very interesting and exciting..

Thank you. [Operator Instructions]. And our next question will come from the line of Serge Belanger with Needham & Company. Your line is now open..

A couple of questions on 7353, now that we are in March and 2Q is just a few weeks away, any possibility that we can get more granularity on when in 2Q we'll see the Phase 3 data? And then on NDA filing planned for second half of '19, what is the gating item for that, is it the open-label safety studies or a CMC component?.

So, it's second quarter, full stop, no more granularity than that and high degree of confidence that we'll hit that. With regard to the NDA, it is the safety study that's the gating factor because we need -- and Bill's mentioned this numerous times, we need 100 patients for 48 weeks at each dose, and that just takes a little bit longer time.

CMC looks great, no issues there. And so, in fact, we're starting to write certain sections of the NDA and CMC is one of them. So yes, you're right, it's the safety study that's the gating factor for filing year end..

And then, now that you have proof-of-concept data and the acute treatment of HAE with 7353, coming out of AAAAI and the feedback you got there, where do you think -- and oral is more of a game changer, but in the acute treatment or prophylactic -- I know your market research definitely supports an oral product for both, but where do you think the key game changer is here?.

I think there is a lot of potential in both of those markets, but I see the prophylactic market as being the biggest market and also the most rapidly growing market for an oral therapy. We believe the patients who have been on acute therapy because they didn't like to have an injection regularly, may look at an oral therapy for prophylaxis.

So, we believe that is growing fast..

Thank you. Your final question comes from Gena Wang with Barclays. Your line is now open..

Just two. First one is also regarding the 9930 Factor D inhibitors.

Just wondering how do you see 9930 compared to other Factor D inhibitors, like particularly against the first generation and the second generation [assays]?.

Sure. Happy to take a stab at that. So, we are very pleased with the profile we've seen. The history of the field indicates that it can be difficult to develop these types of drugs and so that's why we're so excited by the in-vivo proof-of-concept with PD on complement-mediated hemolysis.

The tremendous dose range we've been able to does safely in animals, the very high safety margin, all those factors give us a lot of confidence that we should be able to see effects in humans. We will know that very soon. So, as Jon mentioned before, this is a huge market, and which is, and as Lynne pointed out, growing.

So there's plenty of room for more than one player here..

Yes. And as a practice, we don't compare ourselves to other therapies, other than the fact that there is a bunch of injectables in the clinic and on the market. And so, an oral will be a game changer here.

Your second question, Gena?.

Yes.

So maybe just follow up on the 9930 and if you can share any thoughts on the Phase 1 trial design, indication in trial design, anything you can share with us?.

So, in these circumstances, the first thing we need to understand is the drug levels that we get after oral dosing in single ascending dose and multiple-ascending dose, so that's step one. So that's what we'll be doing..

Okay. And the next question is just quick one on APeX-2.

I know you mentioned before, just wondering if you can remind us how would you define as one attack?.

How would you define what? We couldn't hear that..

One attack..

One attack.

How do you define one attack?.

How do you define one attack? I think the question maybe getting at, if you had an attack recently and then you've symptoms continue with that two attacks or one attack, so there is a time window element to it. So in the field, typically, experts feel that if symptoms happen on Tuesday, when they already happened on Monday.

It's really just one continued attack. So, that type of thing is taken into account in the adjudication of the attack by the investigators..

And that's where I think this investigator confirmed attack is more important than an adjudication panel, because these docs know these patients and having a dialog with the patient helps get clarity on that point..

Thank you. This concludes our question-and-answer session for today. So, now, I'd like to hand the conference back over to Mr. Stonehouse for any closing comments or remarks..

Yes. Thank you. So as always, we appreciate your interest. We're off to a fantastic start in 2019. And clearly, there are some very, very important milestones ahead, and you have our commitment to be focused on delivering those and keeping you up-to-date. And we look forward to a very exciting year in 2019. Thank you. Have a great day..

Ladies and gentlemen, thank you for your participation on today's conference. This does conclude our program. You may all disconnect. Everybody have a good day..